Independent education resourceInformation here does not replace care from a qualified health professional.
Peptide Therapy GuideClear peptide education

Educational guide

Edible, Fluorescent Silk Protein Tags Developed to Weed Out Counterfeit Drugs

Fake or adulterated medicines are a major healthcare security problem, but the huge growth in online pharmacies, coupled with supply chain issues, has made it easier for counterfeiters to profit from their activities. As one approach to help identify counterfe

Written by Peptide Therapy Guide Editorial Team
For education only

This guide cannot diagnose a condition or recommend a personal treatment plan. Discuss medical questions with a qualified professional.

Fake or adulterated medicines are a major healthcare security problem, but the huge growth in online pharmacies, coupled with supply chain issues, has made it easier for counterfeiters to profit from their activities. As one approach to help identify counterfeit medicines, an international research team has harnessed genetically engineered silk worms to create edible tags based on fluorescent silk proteins, which could be placed directly on pills or in a liquid medicine, and which contain codes that can be read by a smartphone app to verify their source and quality.

Reporting on their method in a paper in ACS Central Science “Edible Matrix Code with Photogenic Silk Proteins,” Seong-Wan Kim, at the National Institute of Agricultural Sciences, Republic of Korea, and Young L. Kim, at Purdue University, claimed, “Owing to the unique silk protein structures, this all protein-based code is not only tolerated in liquid solutions with a high alcohol content but also exhibits biocompatibility, photostability, and thermal reliability … The edible code affixed to each medicine can serve as serialization, track and trace, and authentication at the dosage level, empowering every patient to play a role in combating illicit pharmaceuticals.”

Online pharmacies have taken off in recent years, delivering many types of medications directly to consumers’ homes. “Thirty-five thousand to 40 000 active online pharmacies worldwide, with 600 added every month, sell medicines to patients,” the authors wrote. Some of these businesses are legitimate, but others operate illegally, supplying counterfeit drugs that are substandard, incorrectly labeled or laced with unwanted components. In addition, global supply chain problems have made it easy for fake medications to infiltrate the market.

“Counterfeited medication not only poses a serious threat to patient safety and public health but also causes heavy economic losses, accounting for 10% of the global pharmaceutical trade and $200 billion annually,” the investigators further noted. In their paper the team cited figures suggesting that counterfeit malaria and pneumonia medicines may be responsible for some 250,000 child deaths every year.

To instill trust in consumers, pharma companies label the outside packaging of their products with barcodes, QR codes, holograms and radio frequency identifiers, allowing distributors and retailers to manage products throughout the supply chain. But there are no equivalent codes for consumers to verify the source of individual pills or liquid doses that are inside a container. Researchers have developed fluorescent synthetic materials, such as microfibers and nanoparticles, as tracking codes, but the substances are potentially unsafe to consume. As a result, the team noted, “Current anticounterfeiting methods are limited due to the toxicity of the constituent materials and the focus of secondary packaging level protections.”

The investigators wanted to see whether silk, which is an edible and “generally recognized as safe” material, could be placed directly onto medications and made to fluoresce, helping consumers make sure their purchases are what they claim to be.

To do this they genetically modified silkworms to produce silk fibroins—these are edible proteins that give silk fibers their strength—with either a cyan, green or red fluorescent protein attached. They dissolved the fluorescent silk cocoons to create fluorescent polymer solutions, which they applied onto a thin, 9-mm-wide film of white silk in a seven-by-seven grid. Shining blue violet, blue, and green light onto the grid revealed the 3D cyan, green and red square patterns, respectively.

Using optical filters over a phone’s camera, an app the team designed can then scan the fluorescent pattern, decoding the digitized key using a deep learning algorithm and opening up a webpage, which might host information about the drug’s source and authenticity. Some liquid medications are alcohol-based, and encouragingly, when the researchers placed a coded silk film in a clear bottle of Scotch whisky, they found that the fluorescent code was still readable with the app. “Owing to the unique silk protein structures, this all protein-based code is not only tolerated in liquid solutions with a high alcohol content but also exhibits biocompatibility, photostability, and thermal reliability,” they stated.

Finally, they showed that the fluorescent silk proteins are broken down by gastrointestinal enzymes, indicating that the silk codes are not only edible, but also can be digested by the body. “While most fluorescent material-based codes primarily rely on synthetic materials and polymers for inedible applications, the constituent materials of the code reported in this study are all proteins (silk fibroin and fluorescent proteins) that can be easily denatured and degraded by gastric proteolytic enzymes in the digestive system,” the authors commented. “Overall, the digestibility, biocompatibility, and physical stability support the idea that all protein-based edible codes can be easily and safely consumable for on-dose or in-dose authentication in a reliable manner.”

They suggested that placing these edible code appliqués onto pills or in liquid doses could empower patients and their care providers to avoid the unintentional consumption of fake treatments. “We also envision that this edible code can potentially be used for other security and cryptographic applications that require obliteration immediately after being scanned,” they further suggested.

Connected reading

Helpful context for this guide

Source-derived material selected through this article’s indexed topics.

Related questions

01Undruggable or unscreenable?

Another obstacle to discovering new PPI inhibitors is the lack of libraries designed to hunt for them, points out Philippe Roche, PhD, senior scientist at the Integrative Structural and Chemical Biology team at the Cancer Research Center of Marseilles, France. “If you screen PPIs using libraries that were designed for kinases or GPCRs, that’s why you don’t get a lot of good results,” he says. To that end, his group began assembling a library focused on orthosteric inhibitors of PPIs. The result was 2P2Idb, a hand-curated, structural database cataloguing orthosteric inhibitors of PPIs for which the interface had been 3D characterized. From analyzing these known PPI inhibitors, and what structures they had in common, Roche and his colleagues developed a model to predict whether compounds would likely inhibit PPIs. Using this method, 2P2Idb creates an enriched screening library that dramatically increases the hit rate compared to standard libraries. Having proven their success with a small library of 1600 compounds, they are in the process of expanding the library to 10,000 compounds. Once that’s published, “the idea is to make this library available to labs around the world,” Roche says. “We will provide the library free of charge for people to be able to screen PPI targets.”

Source: www.genengnews.com ↗
02How stable is the antibody?

A crucial question often addressed during preclinical development focuses on the in vivo stability of therapeutic antibodies. Increasing the half-life of a therapeutic antibody has several benefits ranging from higher treatment efficacy to increased advantages for the patients who will have a fewer number of therapy sessions and a reduced cost. Given these compelling benefits, following the identification of therapeutic antibodies with the desired specificity, developers usually subject them to a refinement step to increase their stability. This process is often hindered by the lack of reliable experimental tools to predict the half-life of antibodies in patients. The major hurdle of using mouse models to predict antibody stability in the serum lies in the way immunoglobulin proteins are processed by the organism. In mammals, most proteins circulating in the serum undergo constant uptake by endothelial cells and are routed through the endosomes to the lysosomal compartment for degradation. In the endosomes, immunoglobulin G (IgG) proteins are recognized and bound by a transmembrane protein, called the neonatal Fc receptor (FcRn), which mediates their recycling to the plasma membrane and subsequent release back into the serum. As a result, the half-life of IgGs are significantly extended by this mechanism. Since most therapeutic antibodies belong to the IgG class, this recycling system is very relevant for their relative stability in the body. Remarkably, the relative affinity between IgGs and FcRn is extremely disparate between different species, with the mouse receptor showing a much higher affinity than its human counterpart.

Source: www.genengnews.com ↗
P

About the author

Peptide Therapy Guide Editorial Team

Editorial team for Peptide Therapy Guide.

View all articles →